When will Mobocertinib be included in medical insurance?

Mobocertinib (Mobocertinib) is currently on the market in China, but it is not included in medical insurance. Patients need to pay for it in full, so the price is very high. Please consult the local hospital pharmacy for specific prices. Other versions include the Hong Kong version of the original drug Mobotinib, which costs around 7,000 to 8,000 yuan. The generic drug of Mobotinib is mainly a Laotian generic drug. The price is about three to four thousand yuan, which is nearly half cheaper than the original drug. The ingredients of the original drug and the generic drug are the same. Health insurance policies are constantly changing and updating, and the specific drugs and conditions covered may change over time. Therefore, you need to consult the latest Chinese medical insurance policy documents or check with the local medical insurance department to obtain the most accurate information.

Mobosetinib is a new drug used to treat non-small cell lung cancer (NSCLC). Its inclusion in medical insurance usually requires a series of procedures and evaluations, including the drug's clinical effectiveness, safety, cost-effectiveness and other factors. Drug manufacturers are usually required to submit relevant data and materials to China's health authorities in an effort to be included in medical insurance payment coverage.

Once moboxetinib is included in the scope of medical insurance, eligible patients will be able to obtain the drug more easily and enjoy cost reimbursement from medical insurance, thereby reducing the financial burden on patients. However, please note that even if a certain drug is included in the scope of medical insurance, there may still be some conditions and restrictions, which will be determined according to local medical insurance policies.

In view of the dynamic nature of medical insurance policies, it is recommended that you consult your local medical insurance department or medical insurance institution, or consult the latest medical insurance policy documents to obtain the latest information on whether moboxetinib has been included in China's medical insurance coverage.